Lexaria Bioscience (LXRP) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal StudyOctober 22, 2024 | finance.yahoo.comLexaria Updates Current GLP-1 MarketOctober 8, 2024 | finance.yahoo.comLexaria (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 DrugsSeptember 25, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical CollaborationSeptember 24, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 ProgramSeptember 17, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus Oral CapsulesAugust 29, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal StudyAugust 25, 2024 | finanznachrichten.deTinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide MoleculeAugust 16, 2024 | msn.comLexaria Bioscience (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity TreatmentsAugust 9, 2024 | theglobeandmail.comLEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024July 12, 2024 | investorplace.comLexaria Bioscience (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot StudyMay 24, 2024 | theglobeandmail.comLexaria Awards Contract For Third GLP-1 Human Pilot StudyMay 23, 2024 | finance.yahoo.comLexaria begins study on enhanced drug delivery technologyMay 19, 2024 | investing.comDosing Begins in Lexaria's Comprehensive GLP-1 Animal StudyMay 17, 2024 | finance.yahoo.comHere's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn SituationMay 9, 2024 | finance.yahoo.comLexaria gets ethics board okay for oral GLP-1 studyApril 16, 2024 | msn.comLexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot StudyMarch 27, 2024 | theglobeandmail.comLexaria appoints Nelson Cabatuan as CFOMarch 14, 2024 | msn.comLexaria Bioscience (NASDAQ: LEXX) Banking on DehydraTECH(TM) for Major 2024 GrowthMarch 11, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 16, 2024 | finanznachrichten.deWhy Lexaria Bioscience (LEXX) Shares Are MovingFebruary 15, 2024 | msn.comLexaria Unveils Extensive Planned 2024 GLP-1 Study ProgramJanuary 16, 2024 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamJanuary 11, 2024 | finance.yahoo.comLEXX: GLP-1s’ Sweet OpportunityNovember 30, 2023 | msn.comLexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceNovember 1, 2023 | finance.yahoo.comLexaria Bioscience’s Growth Prospects: New Licensing Agreement, Advanced Core Pipeline, and Positive Clinical TrialsOctober 18, 2023 | markets.businessinsider.comLexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSynOctober 13, 2023 | finance.yahoo.comLexaria Bioscience (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery SectorAugust 5, 2023 | msn.comLexaria Bioscience Corp.: Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBDAugust 2, 2023 | finanznachrichten.deLexaria Bioscience (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine StudyJuly 29, 2023 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyJuly 28, 2023 | finanznachrichten.deLexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyJuly 28, 2023 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch ProductsJuly 19, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces 2023 Annual Meeting ResultsMay 10, 2023 | finanznachrichten.deLexaria Announces 2023 Annual Meeting ResultsMay 10, 2023 | finance.yahoo.comLexaria Bioscience (NASDAQ: LEXX) Announces Dosing Completed on Human Nicotine StudyMay 9, 2023 | theglobeandmail.comWhy Is Lexaria Bioscience (LEXX) Stock Down 27% Today?May 9, 2023 | investorplace.comLexaria Bioscience Corp.: Lexaria's Human Clinical Nicotine Study Completes Dosing as PlannedMay 8, 2023 | finanznachrichten.deLexaria’s Human Clinical Nicotine Study Completes Dosing as PlannedMay 8, 2023 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension StudyApril 25, 2023 | finanznachrichten.deLexaria (NASDAQ: LEXX) Revolutionizing Delivery Potential for APIs Using DehydraTECH(TM)April 12, 2023 | theglobeandmail.comLexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBDFebruary 21, 2023 | yahoo.comAnnual Letter from Lexaria CEO, Chris Bunka and Thorough Strategic Update to All StakeholdersJanuary 15, 2023 | stockhouse.comLexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in CanadaJanuary 13, 2023 | benzinga.comLexaria Bioscience Corp.: Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption LevelsDecember 22, 2022 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Human Oral Nicotine Study Begins DosingDecember 20, 2022 | finanznachrichten.deLexaria's Human Oral Nicotine Study Begins DosingDecember 20, 2022 | benzinga.comLexaria Bioscience Turns Focus to Dementia and Diabetes with New StudiesNovember 21, 2022 | finance.yahoo.comLexaria Bioscience progresses with hypertension and oral nicotine studies using DehydraTECHNovember 3, 2022 | proactiveinvestors.comLEXX: DehydraTECH CBD HYPER-H21-4 ResultsOctober 31, 2022 | msn.com Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRP and its competitors with MarketBeat's FREE daily newsletter. Email Address The next assassination attempt won’t be on Trump (Ad)President Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person. I share with you in this special investigative documentary. LXRP Media Mentions By Week LXRP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRP News Sentiment▼0.000.54▲Average Medical News Sentiment LXRP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRP Articles This Week▼00▲LXRP Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies U.S. Gold News Today NioCorp Developments News Today Augusta Gold News Today Augusta Gold News Today Westwater Resources News Today Bunker Hill Mining News Today Mountain Province Diamonds News Today Avalon Advanced Materials News Today Quaterra Resources News Today Pacific Booker Minerals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:LXRP) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
